S&P 500   4,685.80 (+2.05%)
DOW   35,738.19 (+1.45%)
QQQ   397.35 (+2.89%)
AAPL   170.95 (+3.41%)
MSFT   334.91 (+2.67%)
FB   323.80 (+1.87%)
GOOGL   2,943.82 (+2.82%)
AMZN   3,530.92 (+3.02%)
TSLA   1,042.48 (+3.32%)
NVDA   318.54 (+6.05%)
BABA   125.50 (+1.54%)
NIO   33.16 (+2.54%)
CGC   10.90 (+7.39%)
AMD   143.44 (+3.15%)
GE   97.94 (+2.01%)
MU   86.48 (+4.89%)
T   23.15 (-0.56%)
F   19.93 (+3.69%)
DIS   150.23 (-0.09%)
PFE   51.65 (+0.33%)
AMC   30.95 (+7.50%)
ACB   6.40 (+7.20%)
BA   210.08 (+2.04%)
S&P 500   4,685.80 (+2.05%)
DOW   35,738.19 (+1.45%)
QQQ   397.35 (+2.89%)
AAPL   170.95 (+3.41%)
MSFT   334.91 (+2.67%)
FB   323.80 (+1.87%)
GOOGL   2,943.82 (+2.82%)
AMZN   3,530.92 (+3.02%)
TSLA   1,042.48 (+3.32%)
NVDA   318.54 (+6.05%)
BABA   125.50 (+1.54%)
NIO   33.16 (+2.54%)
CGC   10.90 (+7.39%)
AMD   143.44 (+3.15%)
GE   97.94 (+2.01%)
MU   86.48 (+4.89%)
T   23.15 (-0.56%)
F   19.93 (+3.69%)
DIS   150.23 (-0.09%)
PFE   51.65 (+0.33%)
AMC   30.95 (+7.50%)
ACB   6.40 (+7.20%)
BA   210.08 (+2.04%)
S&P 500   4,685.80 (+2.05%)
DOW   35,738.19 (+1.45%)
QQQ   397.35 (+2.89%)
AAPL   170.95 (+3.41%)
MSFT   334.91 (+2.67%)
FB   323.80 (+1.87%)
GOOGL   2,943.82 (+2.82%)
AMZN   3,530.92 (+3.02%)
TSLA   1,042.48 (+3.32%)
NVDA   318.54 (+6.05%)
BABA   125.50 (+1.54%)
NIO   33.16 (+2.54%)
CGC   10.90 (+7.39%)
AMD   143.44 (+3.15%)
GE   97.94 (+2.01%)
MU   86.48 (+4.89%)
T   23.15 (-0.56%)
F   19.93 (+3.69%)
DIS   150.23 (-0.09%)
PFE   51.65 (+0.33%)
AMC   30.95 (+7.50%)
ACB   6.40 (+7.20%)
BA   210.08 (+2.04%)
S&P 500   4,685.80 (+2.05%)
DOW   35,738.19 (+1.45%)
QQQ   397.35 (+2.89%)
AAPL   170.95 (+3.41%)
MSFT   334.91 (+2.67%)
FB   323.80 (+1.87%)
GOOGL   2,943.82 (+2.82%)
AMZN   3,530.92 (+3.02%)
TSLA   1,042.48 (+3.32%)
NVDA   318.54 (+6.05%)
BABA   125.50 (+1.54%)
NIO   33.16 (+2.54%)
CGC   10.90 (+7.39%)
AMD   143.44 (+3.15%)
GE   97.94 (+2.01%)
MU   86.48 (+4.89%)
T   23.15 (-0.56%)
F   19.93 (+3.69%)
DIS   150.23 (-0.09%)
PFE   51.65 (+0.33%)
AMC   30.95 (+7.50%)
ACB   6.40 (+7.20%)
BA   210.08 (+2.04%)
NASDAQ:ILMN

Illumina Stock Forecast, Price & News

$367.60
+15.95 (+4.54%)
(As of 12/7/2021 12:07 PM ET)
Add
Compare
Today's Range
$359.93
$368.44
50-Day Range
$347.28
$421.83
52-Week Range
$335.68
$555.77
Volume
23,817 shs
Average Volume
901,325 shs
Market Capitalization
$57.46 billion
P/E Ratio
60.36
Dividend Yield
N/A
Beta
0.9
30 days | 90 days | 365 days | Advanced Chart
Receive ILMN News and Ratings via Email

Sign-up to receive the latest news and ratings for Illumina and its competitors with MarketBeat's FREE daily newsletter.


Illumina logo

About Illumina

Illumina, Inc. engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through Core Illumina segment, which serves customers in the research, clinical and applied markets, and enable the adoption of a variety of genomic solutions. The firm's products include instruments, kits and reagents, selection tools, and software and analysis. Its services include sequencing and microarray services; proactive instrument monitoring; and instrument services, training, and consulting. The company was founded by David R. Walt, John R. Stuelpnagel, Anthony W. Czarnik, Lawrence A. Bock, and Mark S. Chee in April 1998 and is headquartered in San Diego, CA.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Analytical instruments
Sub-Industry
Life Sciences Tools & Services
Sector
Medical
Current Symbol
NASDAQ:ILMN
CUSIP
45232710
Employees
7,850
Year Founded
1998

Sales & Book Value

Annual Sales
$3.24 billion
Cash Flow
$6.28 per share
Book Value
$67.77 per share

Profitability

Net Income
$656 million
Pretax Margin
25.56%

Debt

Price-To-Earnings

Miscellaneous

Free Float
155,941,000
Market Cap
$57.46 billion
Optionable
Optionable

Company Calendar

Last Earnings
11/04/2021
Today
12/07/2021
Fiscal Year End
12/31/2021
Next Earnings (Estimated)
2/10/2022

Social Links


MarketRank

Overall MarketRank

1.84 out of 5 stars

Medical Sector

579th out of 1,394 stocks

Analytical Instruments Industry

16th out of 33 stocks

Analyst Opinion: 2.2Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.0 5 -4 -3 -2 -1 -












Illumina (NASDAQ:ILMN) Frequently Asked Questions

Is Illumina a buy right now?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Illumina in the last twelve months. There are currently 2 sell ratings, 3 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" Illumina stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ILMN, but not buy additional shares or sell existing shares.
View analyst ratings for Illumina
or view top-rated stocks.

How has Illumina's stock price been impacted by Coronavirus?

Illumina's stock was trading at $246.01 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, ILMN stock has increased by 48.7% and is now trading at $365.91.
View which stocks have been most impacted by COVID-19
.

When is Illumina's next earnings date?

Illumina is scheduled to release its next quarterly earnings announcement on Thursday, February 10th 2022.
View our earnings forecast for Illumina
.

How were Illumina's earnings last quarter?

Illumina, Inc. (NASDAQ:ILMN) announced its quarterly earnings data on Thursday, November, 4th. The life sciences company reported $1.45 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.24 by $0.21. The life sciences company earned $1.11 billion during the quarter, compared to analysts' expectations of $1.04 billion. Illumina had a net margin of 21.17% and a trailing twelve-month return on equity of 15.03%. The business's quarterly revenue was up 39.3% compared to the same quarter last year. During the same period in the prior year, the business posted $1.02 EPS.
View Illumina's earnings history
.

What guidance has Illumina issued on next quarter's earnings?

Illumina updated its FY 2021 earnings guidance on Thursday, November, 25th. The company provided EPS guidance of $5.500-$5.600 for the period, compared to the Thomson Reuters consensus EPS estimate of $5.730. The company issued revenue guidance of $4.41 billion-$4.41 billion, compared to the consensus revenue estimate of $4.35 billion.

What price target have analysts set for ILMN?

10 equities research analysts have issued 1-year price objectives for Illumina's stock. Their forecasts range from $335.00 to $570.00. On average, they expect Illumina's share price to reach $443.20 in the next year. This suggests a possible upside of 21.1% from the stock's current price.
View analysts' price targets for Illumina
or view top-rated stocks among Wall Street analysts.

Who are Illumina's key executives?

Illumina's management team includes the following people:
  • Francis A. deSouza, President, Chief Executive Officer & Director
  • Robert P. Ragusa, Chief Operations Officer
  • Sam A. Samad, Chief Financial Officer & Senior Vice President
  • Phillip G. Febbo, Chief Medical Officer (LinkedIn Profile)
  • Alex Aravanis, CTO, Head-Research & Product Development

What is Francis deSouza's approval rating as Illumina's CEO?

496 employees have rated Illumina CEO Francis deSouza on Glassdoor.com. Francis deSouza has an approval rating of 92% among Illumina's employees. This puts Francis deSouza in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Illumina own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Illumina investors own include NVIDIA (NVDA), Alibaba Group (BABA), Tesla (TSLA), Netflix (NFLX), Walt Disney (DIS), PayPal (PYPL), salesforce.com (CRM), Adobe (ADBE), Visa (V) and Micron Technology (MU).

What is Illumina's stock symbol?

Illumina trades on the NASDAQ under the ticker symbol "ILMN."

Who are Illumina's major shareholders?

Illumina's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Baillie Gifford & Co. (14.06%), Edgewood Management LLC (4.42%), Wellington Management Group LLP (2.09%), Geode Capital Management LLC (1.68%), Polen Capital Management LLC (1.73%) and Janus Henderson Group PLC (1.00%). Company insiders that own Illumina stock include Aimee L Hoyt, Alexander Aravanis, Charles Dadswell, Frances Arnold, Francis A Desouza, Jay T Flatley, Karen K Mcginnis, Mostafa Ronaghi, Oene Mark Van, Omead Ostadan, Phillip G Febbo, Robert P Ragusa, Sam Samad, Susan H Tousi and Susan H Tousi.
View institutional ownership trends for Illumina
.

Which institutional investors are selling Illumina stock?

ILMN stock was sold by a variety of institutional investors in the last quarter, including New York State Common Retirement Fund, Sands Capital Management LLC, First Hawaiian Bank, Morgan Stanley, Baillie Gifford & Co., Wellington Management Group LLP, Capital World Investors, and Janus Henderson Group PLC. Company insiders that have sold Illumina company stock in the last year include Aimee L Hoyt, Alexander Aravanis, Charles Dadswell, Francis A Desouza, Jay T Flatley, Mostafa Ronaghi, Phillip G Febbo, and Susan H Tousi.
View insider buying and selling activity for Illumina
or view top insider-selling stocks.

Which institutional investors are buying Illumina stock?

ILMN stock was acquired by a variety of institutional investors in the last quarter, including Johnson & Johnson, Edgewood Management LLC, Two Sigma Advisers LP, Liontrust Investment Partners LLP, Renaissance Technologies LLC, MWG Management Ltd., Arrowstreet Capital Limited Partnership, and Alliancebernstein L.P..
View insider buying and selling activity for Illumina
or or view top insider-buying stocks.

How do I buy shares of Illumina?

Shares of ILMN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Illumina's stock price today?

One share of ILMN stock can currently be purchased for approximately $365.91.

How much money does Illumina make?

Illumina has a market capitalization of $57.19 billion and generates $3.24 billion in revenue each year. The life sciences company earns $656 million in net income (profit) each year or $6.09 on an earnings per share basis.

How many employees does Illumina have?

Illumina employs 7,850 workers across the globe.

Does Illumina have any subsidiaries?

The following companies are subsidiares of Illumina: Advanced Liquid Logic Inc., Affomix Corporation, BlueBee, BlueBee Belgium BVBA, BlueBee Holding BV, BlueGnome Ltd, BlueGnome Ltd., Conexio Genomics, Conexio Genomics Pty Ltd., Edico Genome, Edico Genome Corp., Enancio, Enancio SAS, Epicentre Biotechnologies, Epicentre Technologies Corporation, FC Ops Corp., GenoLogics, Grail, Helixis, Illumina (China) Scientific Co Ltd, Illumina AB, Illumina Australia Pty. Ltd., Illumina Belgium BVBA, Illumina Brasil Produtos de Biotecnologia Ltda., Illumina Cambridge Ltd., Illumina Canada Inc., Illumina Canada ULC, Illumina Denmark ApS, Illumina Finland Oy, Illumina France Holding Sarl, Illumina France Sarl, Illumina GmbH, Illumina Hong Kong Limited, Illumina Iceland ehf, Illumina India Biotechnology Private Limited, Illumina Ireland Commercial Limited, Illumina Italy S.r.l., Illumina K.K. Japan, Illumina Korea Ltd., Illumina Netherlands B.V., Illumina New Zealand Limited, Illumina Norway AS, Illumina Productos de Espana S.L.U., Illumina Rus, Illumina Rus LLC, Illumina Shanghai (Trading) Co Ltd, Illumina Shanghai (Trading) Co Ltd Beijing Branch, Illumina Shanghai (Trading) Co. Ltd., Illumina Singapore Pte. Ltd., Illumina Software Inc., Illumina Switzerland GmbH, Illumina US Manufacturing Operations Inc., Liquid Logic, Moleculo, NextBio, Solexa, Verinata Health, Verinata Health Inc., and thromboDx BV.

When was Illumina founded?

Illumina was founded in 1998.

What is Illumina's official website?

The official website for Illumina is www.illumina.com.

Where are Illumina's headquarters?

Illumina is headquartered at 200 ILLUMINA WAY, SAN DIEGO CA, 92122.

How can I contact Illumina?

Illumina's mailing address is 200 ILLUMINA WAY, SAN DIEGO CA, 92122. The life sciences company can be reached via phone at (858) 202-4500, via email at [email protected], or via fax at 858-202-4766.


This page was last updated on 12/7/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.